The case for & against
Bull & Bear analysis
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to innovative treatments for chronic and life-threatening conditions, particularly in pulmonary arterial hypertension (PAH) and pulmonary fibrosis. As a leader in the specialty pharma sector, United Therapeutics has positioned itself with advanced therapeutic products like Tyveso and Ralenapeg, promising substantial improvements in patient outcomes. Their emerging focus on organ manufacturing further underscores their commitment to addressing unmet medical needs while enhancing their revenue potential.
Bull says
- ↑Q1 revenue $782M (+11% YoY) driven by Tyveso $458M (+9% YoY)
- ↑Forecasting $4B revenue run rate by end-2027 with pipeline launches
- ↑Positive Phase III Tyvaso results in IPF and Ralenapeg filings due Q3
- ↑$1B share buyback authorized; operating cash flow exceeding $1B annually
- ↑Leading inhaled therapies with strong patient retention and prescribing trends
- ↑High earnings yield, strong profitability, positive momentum and low leverage
Bear says
- ↓Rising PAH entrants like Eutrepia and generics pressuring market share
- ↓Revenue run-rate target hinges on Ralenapeg and Tyvaso performance
- ↓Analyst earnings revisions negative; growth projections under question
- ↓Short interest elevated, reflecting bearish sentiment amid competition
- ↓Operational and pharmacy execution issues risk revenue consistency
- ↓Negative growth outlook and lack of dividend reduce income appeal
Investment themes with UTHR
Companies with strong fundamentals and stability
Genetic and drug innovations driving medical breakthroughs
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- For the first quarter of 2026, we recorded $782 million in total revenue.
- Total revenue for the first quarter was $458 million. While sales of Nebuli Pet Tyveso lagged a little bit over the quarter, Tyveso DPI contributed 9% year-over-year growth, driven by an increase in patient demand.
- we are seeing favorable trends in our underlying demand metrics.